Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

There is no scientific rationale for race-based research.

Hoover EL.

J Natl Med Assoc. 2007 Jun;99(6):690-2.

2.

Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.

Tutton R, Smart A, Martin PA, Ashcroft R, Ellison GT.

J Law Med Ethics. 2008 Fall;36(3):464-70. doi: 10.1111/j.1748-720X.2008.292.x. Review.

PMID:
18840237
3.

Medicalisation of race.

Duster T.

Lancet. 2007 Feb 24;369(9562):702-4. Review. No abstract available.

PMID:
17321318
4.

Racial differences in heart failure therapeutics.

Ishizawar D, Yancy C.

Heart Fail Clin. 2010 Jan;6(1):65-74. doi: 10.1016/j.hfc.2009.08.006. Review.

PMID:
19945062
5.

Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?

Ferdinand KC.

J Law Med Ethics. 2008 Fall;36(3):458-63. doi: 10.1111/j.1748-720X.2008.291.x. Review.

PMID:
18840236
6.

Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.

Echols MR, Yancy CW.

Vasc Health Risk Manag. 2006;2(4):423-31. Review.

7.

Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.

Ferdinand KC.

Expert Rev Cardiovasc Ther. 2005 Nov;3(6):993-1001. Review.

PMID:
16292990
8.

Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.

Colvin-Adams M, Taylor AL.

Cleve Clin J Med. 2007 Mar;74(3):227-34. Review.

PMID:
17375804
10.

How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.

Kahn J.

Yale J Health Policy Law Ethics. 2004 Winter;4(1):1-46. Review. No abstract available.

PMID:
15052858
11.

Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.

Ferdinand KC, Elkayam U, Mancini D, Ofili E, PiƱa I, Anand I, Feldman AM, McNamara D, Leggett C.

Am J Cardiol. 2014 Jul 1;114(1):151-9. doi: 10.1016/j.amjcard.2014.04.018. Review.

12.

Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.

Cole RT, Kalogeropoulos AP, Georgiopoulou VV, Gheorghiade M, Quyyumi A, Yancy C, Butler J.

Circulation. 2011 May 31;123(21):2414-22. doi: 10.1161/CIRCULATIONAHA.110.012781. Review. No abstract available.

13.

Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.

Ferdinand KC, Serrano CC, Ferdinand DP.

Curr Hypertens Rep. 2002 Aug;4(4):311-8. Review.

PMID:
12117459
14.

The impact of race on response to RAAS inhibition.

Wallace TW, Drazner MH.

Curr Heart Fail Rep. 2005 Aug;2(2):72-7. Review.

PMID:
16036054
15.

Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.

Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J.

J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S. Review.

16.

Race in biological and biomedical research.

Cooper RS.

Cold Spring Harb Perspect Med. 2013 Nov 1;3(11). pii: a008573. doi: 10.1101/cshperspect.a008573. Review.

17.

Social diversity in humans: implications and hidden consequences for biological research.

Duster T.

Cold Spring Harb Perspect Biol. 2014 May 1;6(5):a008482. doi: 10.1101/cshperspect.a008482. Review.

18.

Race and racialism in scientific research and publication in the Journal of the National Medical Association.

Odocha O.

J Natl Med Assoc. 2000 Feb;92(2):96-8. Review. No abstract available.

Supplemental Content

Support Center